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ABSTRACT 
TITLE 
Retrospective study with follow up of children with hepatoblastoma. 
DEPARTMENT 
Paediatric surgery 
NAME OF THE CANDIDATE 
Dr.Soumitra Saha 
DEGREE AND SUBJECT 
M.Ch. Paediatric Surgery 
NAME OF THE GUIDE 
Dr. Immanuel Sampath Karl 
AIMS AND OBJECTIVES 
To retrospectively review our single centre experience with neoadjuvant chemotherapy and 
surgery in hepatoblastoma. 
MATERIALS AND METHODS 
This is a retrospective study with follow-up of children with hepatoblastoma during the period 
from January 2003 to December 2012 at Christian Medical College and Hospital, Vellore 
(CMCH). All 28 (N=28) cases diagnosed and completely treated in CMCH under pediatric 
	

surgery and pediatric oncology were included in this study.Data were retrospectively collected 
from surgical and medical records. Patient characteristics, mode of diagnosis, treatment 
modalities, follow-up and disease free survival were analyzed. Data entry was done using 
Microsoft excel. Data analysis was done using Statistical Package for Social Sciences (SPSS) 
version 16.
RESULTS 
Mean age of presentation was 28.22 months. Male:female ratio was 3.6:1. 27 cases had raised 
AFP at presentation. Most patients were managed after needle biopsy with 4 cycles of PLADO, 
surgery and 2 more cycles of PLADO. Among 28 patients, 7 patients did not undergo surgery. 1 
patient is disease free after getting full course of chemotherapy without surgery. Remaining 20 
patients underwent hepatic resection. There was no intra operative mortality. Among these 20 
patients, 13 patients are disease free with near follow-up 3 years. Other 7 patients died. 
CONCLUSION 
65% patients who underwent hepatic resection are disease free after mean follow-up of 
approximately 3 years. One patient is disease free after getting full course of chemotherapy 
without surgery. However 7 patients who were originally seen did not undergo surgery for a 
variety of reasons making the overall survival 50%. 
 
KEYWORDS: Hepatoblastoma, AFP, PLADO 
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INTRODUCTION 
 
Hepatoblastoma (HB) accounts around 80% of malignant liver tumor among pediatric age 
group1,2. It is a rare pediatric a pediatric neoplasm. Its incidence is about 1.5 per million. It 
comprises only about 1% of all pediatric malignancies3. 
 
Till 1970, surgery was only treatment modality for HB. In the past children with HB were treated 
with surgery alone and there was around 30% relapse rate. Then we gradually came to know that 
HB is a chemo sensitive tumor. Tremendous advances in chemotherapy occurred in last 2 
decades. In recent era, successful treatment of HB includes neoadjuvant chemotherapy, surgery 
and adjuvant chemotherapy. 
 
Studies related to HB published in different Indian journals were comparatively dealt with small 
number of study group and study period as compared to western studies. 
 
 
This study deals with our experience in the management of hepatoblastoma 
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AIMS AND OBJECTIVES 
 
Retrospectively review our experience with hepatoblastoma. 
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REVIEW OF LITERATURE 
 
After neuroblastoma and Wilms’ tumor, third most common abdominal neoplasms in pediatric 
age group is primary tumor of liver 4. Among primary tumor of liver HB is the most common. 
 
 
EPIDEMIOLOGY, BIOLOGY, and GENETICS 
 
HB accounts around 80% of malignant liver tumor among pediatric age group1,2. It is a rare 
pediatric a pediatric neoplasm. Its incidence is about 1.5 per million. It comprises only about 1% 
of all pediatric malignancies3. It affects primarily young children between 6 months to 3 years. 
 
 
Following genetic syndromes are associated with HB and other malignancies5: 
 
1. Beckwith – Wiedemann syndrome 
2. Li – Fraumeni syndrome 
3. Trisomy 18 
4. Familial adenomatous polyposis 
5. Glycogen storage disease type I-IV 
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PATHOLOGY  
 
International Society of Pediatric Oncology ( Epithelial ) liver tumor study group (SIOPEL) 
classified HB in the following  histological subtypes 
 
 
1. HB, Wholly Epithelial Type 
2. Fetal  
3. Embryonal / mixed fetal and embryonal  
4. Macrotrabecular (MT) 
5. Small cell undifferentiated (SCU; formerly anaplastic) 
6. HB,Mixed Epithelial and Mesenchymal Type ( HB-MEM ) 
7. Without teratoid features 
8. With teratoid features 
9. HB, Not Otherwise Specified ( HB-NOS) 
 
 
 
Prognostically fetal subtype has favorable biology. Macrotrabecular variant (MT) and small cell 
undifferentiated (SCU) have unfavorable prognosis. MT is difficult to distinguish from 
hepatocellular carcinoma. SCU is not associated with elevated serum alpha fetoprotein 5,6,7,8,9 . 
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DIAGNOSIS  
 
Clinical presentation 
 
HB is most commonly seen between 6 months and 3 years of age. It usually presents with right 
upper quadrant or epigastric mass. Rarely children present with fatigue, anorexia, weight loss, 
jaundice due to biliary obstruction. 
 
Laboratory evaluation 
 
Routine laboratory investigation 
Children with HB may present with thrombocytosis10,11. 
 
Serum alpha fetoprotein (AFP) 
It is the most important tumor marker. It will be elevated in 90% of children with HB. It is the 
protein produced by fetal liver. Its t1/2 is around 7 days. It is present in very high concentrations 
at birth. Then it rapidly declines to adult levels by 8 months of age. So in infants younger than 8 
months, AFP levels must be interpreted carefully. Markedly elevated AFP in a child with a liver 
mass signifies that the mass is most likely to be HB. Although milder elevation may be seen with 
mesenchymal hamartoma12 or tertoma13. HB that fails to express (AFP<100 ng/ml) is 
biologically more aggressive with a poor prognosis. 
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Radiology  
 
Ultrasonography should be first investigation to know about the organ of origin. Contrast 
enhanced abdominal computed tomography (CECT) scan will be next radiological investigation. 
Chest X-ray and CT scan are  essential part of initial radiographic evaluation. It will rule out 
pulmonary metastasis. 
 
 
 
 
 
PRETEXT, STAGING, AND RISK GROUP STRATIFICATION 
 
PRETEXT stands for pre treatment extent of disease at diagnosis.  
 
POST-TEXT stands for post-treatment extent of tumor after neoadjuvant chemotherapy. 
 
First time the word “PRETEXT” was used by SIOPEL – 114. 
 
It divides children with HB under different risk groups. It helps to plan the treatment. It also tells 
about the outcome. 
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Figure III-1 5 
 
PRETEXT system divides liver into four “sections”.  
Left lobe of liver: Lateral, Medial section.  
Lateral section: Segments II, III.  
Medial section: Segment IV.  
Right lobe: Anterior, Posterior section. 
Anterior section: Segments V, VIII.  
Posterior section: Segments VI, VII.  
Segment I: Caudate lobe. 
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Figure III-2 5 
V”: Involvement of venacava or all three hepatic veins.  
“P”: Involvement of main portal or both portal branches.  
“C”: Involvement of caudate lobe.  
“E”: Extrahepatic contiguous growth (Involvement of diaphragm or stomach).  
“M”: Distant metastases (mostly lungs) 15. 
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The Children’s Oncology Group (COG) uses traditional COG (Evans) staging 
system: 
 
 
Stage I: Complete gross resection at diagnosis with clear margins 
 
 
Stage II: Complete gross resection at diagnosis with microscopic residual disease at the margins 
of resection. 
 
 
Stage III: Biopsy only at diagnosis, or gross total resection with nodal involvement or tumor 
spill or incomplete resection with gross intrahepatic disease. 
 
 
Stage IV: Metastatic disease at diagnosis. 
 
 
There are certain pitfalls of Evans staging system. It relies on resection decision by the sugeon at 
diagnosis.  
 
Currently COG uses PRETEXT as surgical guidelines 16.

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Currently COG stratifies the patients into following risk categories: 
 
 
 
Very low risk group:  
PRETEXT I / II tumor with pure fetal histology (PFH). Resected margin should be >1cm. 
 

Low risk group:  
Any histology with PRETEXT I / II tumor. . Resected margin should be >1cm. 
 
 

Intermediate risk:  
PRETEXT stage III tumor ( includes SCU histology). 
 
 
 
High risk:  
Stage IV tumors  
All tumors with AFP level less than 100 ng/ml at diagnosis. 


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SIOPEL uses PRETEXT for risk stratification. PRETEXT has a tendency to over stage. It can 
also be used to monitor the tumor following preoperative chemotherapy. 
 
Current SIOPEL Risk Stratification:  
Standard risk group:  
PRETEXT stage I, II and III tumor 
High risk group:  
PRETEXT stage IV tumor 
Metastasis at the time of diagnosis 
SCU histology 
AFP level less than 100 ng/ml 
 
 
TREATMENT STRATEGY, CHEMOTHERAPY, AND SURGERY 
 
It is now clear that surgery alone is not sufficient to cure HB. Since 1970, evidences were started 
accumulating regarding chemosensitive  nature of HB. In 1980, there was a major impact on 
survival following introduction of cisplatin and doxorubicin. Now cisplatin became the backbone 
of chemotherapy. 
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Advantages of neoadjuvant (preoperative) chemotherapy:  
 
 
1. It reduces the tumor volume 
 
 
2. It makes the tumor more solid and better demarcated from remaining liver. There is also 
less intraoperative bleeding. 
 
 
3. It makes the tumor resectable, reduces surgical morbidity. It provides more time to make 
plans like liver transplantation. 
 
 
4. Lung metastases may completely disappear following neoadjuvant chemotherapy. 
 
 
 
Every HB child should receive neoadjuvant chemotherapy. Cisplatin monotherapy is  
comparable with cisplatin/doxorubicin combination chemotherapy (PLADO) in the treatment of 
PRETEXT I, II and III tumor 17. 
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Figure III-3 5 
 
 
Similar to SIOPEL, GPOH study group in their recent trial (HB 99) concluded neoadjuvant 
chemotherapy should be given in all patients 6,19 . 
 
 
COG study group in their recent trial (AHEP-0731) concludes PRETEXT I and II tumor should 
be resected at diagnosis with 1 cm of margin. Best option for POSTTEXT III d central tumor is 

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mesohepatectomy. Transplantation is preferred option if any tumor involving major vascular 
inflow or outflow 7,17 .  
 
 
 
Currently postoperative (adjuvant) chemotherapy is recommended by all study group. The 
backbone of all chemotherapy regimen is cisplatin. But there is one small exception.  
 
According to COG AHEP-0731 no chemotherapy is required for pure PFH children those 
underwent resection at diagnosis 10,20,21 . 
 
 
Currently COG uses the following chemotherapy regimen: 
 
Low-risk tumors: Cisplatin / 5FU (Fluorouracil) / Vincristine (C5V). 
 
Intermediate-risk tumor: C5V + Doxorubicin. 
 
High-risk tumor: New agents (Irinotecan) will be investigated with upfront window therapy22
. 
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Cisplatin monotherapy with PLADO was compared in SIOPEL3 23. In SIOPEL3 only 
SUPERPLADO (Cisplatin / Carboplatin / Doxorubicin) was used for high-risk group18. In the 
current SIOPEL4, for high-risk group, dose-dense cisplatin-based chemotherapy is being used 24. 
 
 
In the GPOH trial (Hepatoblastoma 94), Ifosfamide, Cisplatin and Doxorubicin) were used8. 
 
 In the GPOH trial (Hepatoblastoma 99), IPA was used for standard risk and CARBO/VP16 
(Caboplatin/Etoposide) was used for high risk19. 
 
 
In the Japanese trial, Cisplatin and Pirarubicin were used to treat standard risk.  
 
In the same trial ITEC (Ifosfamide/Pirarubicin/Etoposide/Carboplatin) + HACE (Hepatic artery 
chemoembolilization) were used for high-risk patients25. 
 
In both North America and Europe, irinotecan ± doxorubicin, has been used for patients with 
relapse26,27. 
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Following important conclusions were mentioned in SIOPEL 3: 
 
1. Using standard treatment, around 25% of patients who present with metastasis are finally 
cured. 
2. Alternative chemotherapy and surgical resection should be thought to treat pulmonary 
metastasis when there was no response following chemo. 
3. Microscopic positive margin following resection may not be a poor prognostic factor 
when there is excellent response following chemo. 
4. Liver transplantation or major resection should be considered in unresectable 
hepatoblastoma 28,29,31,32,33. 
 
 
 
In the COG trial, AHEP-0731, following decisions were made: 
 
1. Very-low-risk patients with PFH should be resected at presentation without any 
chemotherapy. 
 
 
2. Low-risk patients with non-PFH should be resected at diagnosis and followed by 2 cycles 
of C5V 
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
 
3. Intermediate-risk group patients with stage I and II SCU, or any stage III HB should 
receive doxorubicin in addition to C5V therapy. 
 
 
4. High-risk patients with metastasis at presentation or initial AFP < 100ng/ml should be 
treated with irinotecan followed by C5VD. 
 
 
Liver transplantation for hepatoblastoma: 
 
Due to availability of effective chemotherapy, children with unresectable HB can undergo total 
liver resection followed by orthotopic liver transplantation (OLT) 35. 
 
 
Transplantation outcomes for hepatoblastoma: 
 
Overall survival at 10 years following primary transplantation was around 85%. But it was 
dropped into 40% when children underwent rescue transplantation36. 
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Indications and contraindications for OLT:  
 
a) Multifocal PRETEXT IV tumor at diagnosis. 
 
 
b) Unifocal PRETEXT IV tumor at diagnosis. 
 
 
c) POSTTEXT III tumor involving major vascular outflow. 
 
 
d) POSTTEXT III tumor involving major vascular inflow. 
 
e) Rescue Transplantation 37,38. 
 
 
 
Transplantation versus Extreme resection: 
 
Among transplantation and extreme resection, later is the better option for avoiding long-term 
immunosuppression. Extensive resection, with vessels reconstruction should be done by expert 
surgical team 39,40,41. 
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Transplantation in HB child with lung metastasis at presentation: 
 
 
Absolute contraindication: 
 
a) Persistent lung metastases which are non-responsive to chemotherapy. 
 
b)  Lung metastases which are difficult for surgical resection. 
 
 
Relative contraindication: 
 
Lung metastases which are stable or progressive disease following preoperative chemotherapy. 
 
If the lung has >4 nodules in the same lobe, lobectomy is preferable rather than 
metastatectomy42. 
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Rescue transplantation in local relapse: 
 
In comparision with rescue transplantation there is always superior outcome following primary 
transplantation. 
 
 
Live-donar liver transplantation (LDLT) is the new trend 36,43,44. 
 
PLUTO: 
Full form is Pediatric Liver Unresectable Tumor Observatory 
 
It is a worldwide electronic registry for liver transplantation45. The website of registry is 
http://pluto.cineca.org/access. 
 
 
Hepatic arterial chemoembolisation and Transarterial chemoembolisation 46: 
 
This technique is quite popular in China.  
 
Chemotherapeutic drugs have used in various combination of cisplatin, doxorubicin, vincristine, 
pirarubicin, mitomycin etc.  
 

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Most often it is used as a palliative care. 
 
Cisplatin related hearing problem: 
This is more common in children younger than 5 years of age. There is high frequency hearing 
loss.  
COG AHEP 0731 trial is trying to decrease the dose of cisplatin in low-risk group 47,48. 
 
Childhood Hepatic Tumor International Collaboration (CHIC): 
This trans-atlantic development is eventually going to benefit children with liver tumor. 
Prognosis for recurrent or progressive HB depends on following factors: 
1. Site of recurrence 
2. Prior treatment 
3. Multidrug chemotherapy resistance 
4. Individual patient consideration 
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MATERIALS AND METHODS 
 
 
STUDY DESIGN AND STUDY DESIGN 
This is a retrospective study with follow-up of children with hepatoblastoma during the period 
from January 2003 to December 2012 at Christian Medical College and Hospital, Vellore 
(CMCH). All the children who came under pediatric surgery and pediatric oncology were 
included in this study.  
 
STUDY PERIOD 
The study has been done over a period of ten years (January2003 - December 2012). 
 
 
SAMPLE SIZE 
Hepatoblastoma is a rare pediatric a pediatric neoplasm. Its incidence is about 1.5 per million. So 
all 28 (N=28) cases diagnosed and completely treated in CMCH under pediatric surgery and 
pediatric oncology were included in this study. 
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INCLUSION CRITERIA 
All children who were diagnosed and treated in CMCH under pediatric surgery and pediatric 
oncology. 
EXCLUSION CRITERIA 
Children with age above 15 years were excluded from the study. 
 
DATA COLLECTION 
Data were retrospectively collected from surgical and medical records. Patients’ contact 
addresses and phone numbers were also collected from medical records and they were invited to 
visit hospital for follow-up. 
This included sex, age at presentation, mode of presentation, mode of diagnosis, 
histopathological types, alpha-fetoprotein (AFP) level at presentation, β-HCG level at 
presentation, liver function test (LFT), creatinine, pulmonary and other metastasis at 
presentation, PRETEXT (Pretreatment extent of disease) staging, number of PLADO cycles or 
any other chemotherapeutic drugs used as neoadjuvant chemotherapy, POSTTEXT 
(Posttreatment extent of disease) staging before surgery, AFP level just before surgery, types of 
hepatectomy, reasons behind not undergoing hepatectomy, number of PLADO cycles or any 
other chemotherapeutic drugs used as adjuvant chemotherapy, recurrences and metastasis 


following primary treatment, any redosurgeries, disease free survival, AFP at last follow-up, any 
deaths during follow-up. 
STATISTICAL METHODS 
Data entry was done using Microsoft excel. 
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RESULTS AND ANALYSIS 
CHARACTERISTICS OF STUDY POPULATION (N=28) 
Total number of children who were diagnosed and treated in CMCH under pediatric 
surgery and pediatric oncology during the period from January 2003 to December 2012 
was 28. 
SEX RATIO 
Among 28 children, 22 were male and 6 were female (3.6:1). 
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AVERAGE AGE OF PRESENTATION 
Average age of presentation was 28.22 months. 
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FIGURE V-2 Average age of presentation 
 
MODE OF PRESENTATION 
All 28 patients presented with abdominal mass. Along with abdominal mass 3 presented 
with jaundice and 1 presented with male isosexual precocious puberty. 
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MODE OF DIAGOSIS 
Among 28 children, 23 (82.14%) were underwent trucut biopsy. Without biopsy, on the 
basis of CT findings and raised AFP, 4 (14.28%) were diagnosed to have hepatoblastoma. 
Only 1 child (3.57%) underwent open biopsy for diagnosis. 
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FIGURE V-3 MODE OF DIAGNOSIS 
 
 
 


HEPATOBLASTOMA HISTOLOGICAL SUBTYPES 
Among 28 children, 17 patients had epithelial variety (60.71%). Among these, one had 
small cell undifferentiated and one had macrotrabecular subtypes. Another child 
developed macrotrabecular type of metastasis. Prognostically both small cell 
undifferentiated and macrotrabecular variants have unfavorable biology.  
Remaining, 11 children had mixed epithelial and mesenchymal type (39.28%).  
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FIGURE V-3 Hepatoblastoma histological subtypes 
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FIGURE V-4 Hepatoblastoma, epithelial type. Black arrow – embryonal. Red arrow – fetal. H&E 20x. 
 
FIGURE V-5 Hepatoblastoma, mixed epithelial and mesenchymal. Black arrow – embryonal. Red arrow – fetal. Green arrow – 
osteoid. Blue arrow – immature mesenchyme. H&E 20x. 
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FIGURE V-6 Hepatoblastoma, teratoid type. Epithelial elements. H&E 40x. 
 
FIGURE V-7 Hepatoblastoma, teratoid type. Cartilage and smooth muscle bundles. H&E 10x 

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 FIGURE V-8 Hepatoblastoma, undifferentiated type. H&E 40x 
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AFP AT PRESENTATION (IU/ml) 
Normal value is up to 5.5 IU/ml. Among 28 children, only 1 child presented with 4.32 IU/ml 
AFP level and tumor subtype was small cell undifferentiated hepatoblastoma. Remaining 27 
children presented with >100 IU/ml AFP level (Max. value 3500000 IU/ml). 
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FIGURE V-9 AFP level (IU/ml) at presentation 
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ELEVATED β-HCG (mIU/ml) AT PRESENTATION 
Among 28 children, 1 boy and 1 girl presented with high β-HCG (mIU/ml) level. Normal β-HCG 
level is up to 5.0 mIU/ml. Both of them died. 
No. of patients Β-HCG level at presentation (mIU/ml) 
1 boy 167 mIU/ml 
1 girl 17.11 mIU/ml 
 
 
FIGURE V-10 BOY WITH HIGH β-HCG & MALE ISOSEXUAL PRECOCIOUS PUBERTY (ENLARGED 
PENIS) 
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LIVER FUNCTION TEST  (LFT) & CREATININE AT THE TIME 
OF PRESENTATION 
Among 28 children, 3 presented with abnormal LFT with raised total and direct bilirubin. On the 
other hand, all had normal creatinine at beginning. 
 
METASTASIS AT PRESENTATION 
Among 28 children, 2 presented with multiple lung metestastasis. 
 
 
 
FIGURE V-11 Multiple lung metastasis at presentation 
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NEOADJUVANT (PREOPERATIVE CHEMOTHERAPY) 
 
Preoperatively all 28 patients received neoadjuvant chemotherapy. On an average the 
patients received 4 cycles of PLADO (cisplatin/doxorubicin combination chemotherapy), 
ranging from 2 to 6 cycles.  
 
Following 2 cycles of PLADO regimen, one child received 7 cycles JEB regimen 
(Carboplatin, Etoposide, Bleomycin).  
 
 
One boy received 3 cycles of PLADO at the beginning. There was no significance 
response, hence his treatment was individualized to IVA (Vincristine, Actinomycin, 
Ifosfamide) alternate with JEB (Carboplatin, Etoposide, Bleomycin). 
 
Another boy received 4 cycles of PLADO followed by rapid COJEC protocol    
(Vincristine, Carboplatin, Etoposide, Cyclophosphamide) due to simultaneous 
presentation of hepatoblastoma and right paravertebral neuroblastoma. 
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SIMULTANEOUS PRESENTATION OF HEPATOBLASTOMA & NEUROBLASTOMA 
 
FIGURE V-12 Hepatoblastoma (II V0 P0 E0 C0 M0) 
 
FIGURE V-13 Right paravertebral Neuroblastom 
Child was treated successfully 

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AFP LEVEL (IU/ml) LEVL AFTER NEOADJUVANT 
CHEMOTHERAPY 
Child with small cell undifferentiated tumor had AFP value of 2.68 IU/ml. Following 
neoadjuvant chemotherapy AFP value of 4 children came down within 10 to 100 IU/ml. 
The AFP values of remaining 23 children were between 100 IU/ml and 30000 IU/ml). 
 
 
 
FIGURE V-14 AFP level (IU/ml) after neoadjuvant chemotherapy 
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PRETEXT AND POSTTEXT STAGING 
Among 28 patients, PRETEXT and POSTTEXT staging were done on 25 patients. PRETEXT 
staging distribution was as follows; PRETEXT Stage I 16% (n=4), Stage II 48% (n=12), Stage 
III 24% (n=6), and Stage IV 12% (n=3). 
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FIGURE V-15 PRETEXT Staging 
 
 
 


 
 
FIGURE V-16 [Top] PRETEXT (III) and [Bottom] POSTTEXT (III) of the same child. Child underwent right 
hemihepatectomy. 
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FIGURE V- 17 [Top] PRETEXT (II V0 P0 E0 C0 M0) and [Bottom] POSTTEXT (II V0 P0 E0 C0 M0) of the same 
child. Child underwent nonanatomic resection. 
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FIGURE V-18 [Top] PRETEXT (IIV0P0E0C0M0) and [Bottom] POSTTEXT (IIV0P0E0C0M0) of the same child. 
Child underwent right hemihepatectomy. 
 
 
 


 
FIGURE V- 19 [Top] PRETEXT (IIV0P0E+C0M0) and [Bottom] POSTTEXT (IIV0P0E+C0M0) of the same child. 
Not much response in respect to size. Child underwent right hemihepatectomy 
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FIGURE V- 20 [Top] PRETEXT (I V0 P+ E0 C0 M0) and [Bottom] POSTTEXT (I V0 P+ E0 C0 M0) of the same 
child. Child underwent left hemihepatectomy. 
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FIGURE V- 21 [Top] PRETEXT (II V0 P+ E0 C0 M+) and [Bottom] POSTTEXT (II V0 P0 E0 C0 M0) of the same 
child. Child underwent right hemihepatectomy. 
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FIGURE V- 22 [Top] PRETEXT (II V0 P0 E0 C0 M0) and [Bottom] POSTTEXT (I V0 P0 E0 C0 M0) of the same 
child. Child underwent left hemihepatectomy. 
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HEPATECTOMY 
Among 28 (N=28) patients, 20 patients underwent hepatic resection (71.42%). 
Remaining 7 patients did not undergo surgery. Extensive residual disease with metastasis 
was the major reason behind this.  
 
TYPES OF HEPATECTOMY 
Among 20 patients, 7 underwent right hemihepatectomy, 3 underwent right 
trisectionectomy, 4 were treated with left hemihepatectomy, only 1 underwent left lateral 
sectionectomy and remaining 5 children underwent segmentectomy. 
 
         FIGURE V-23 Child successfully underwent right trisectionectomy 
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ADJUVANT CHEMOTHERAPY 
Postoperatively on an average children received 2 cycles of cisplatin and doxorubicin (PLADO). 
 
SPECIAL SITUATION 
One patient seems cured with chemotherapy alone. This 3 years girl presented with exomphalos 
and the liver mass was protruding through it. At presentation AFP was 856 IU/ml. The tumor 
was central in location and PRETEXT stage was III. 6 cycles of PLADO were given. 
POSTTEXT stage was III. Recent AFP value was 0.596 IU/ml. PET-CT was done and showing 
no tumor activity. Disease free survival was 10 months. 
 
 
FIGURE V-24 AT PRESENTATION (PRETEXT II V0 P+ E+ C0 M0) 
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FIGURE V-25 POSTTEXT (II V0 P+ E+ C0 M0) 
 
 
 
 
 
 
FIGURE V-26 PET-CT. NO RESIDUAL DISEASE. 
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TUMOR RELAPSE 
Among 28 children, 4 had recurrent disease at remaining liver tissue and 3 had distant metastasis 
at lung, brain and skull. All 7 patients died. 
 
 
FIGURE V-27 Recurrence at segment V, status left hepatectomy. 
 
 
FIGURE V-28 Metastasis at left lower lobe of lung. 
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FIGURE V-29 Metastasis at left fronto-parietal lobe. 
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SURVIVAL ACCORDING TO PRETEXT STAGE 
The overall survival according to the PRETEXT stage was as follows: PRETEXT I 50%, 
PRETEXT II 91.66%, PRETEXT III 16.66% and PRETEXT IV 0%. 
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FIGURE V-30 Survival according to PRETEXT stage 
OUTCOME 
• Among 28 patients, 7 patients did not undergo surgery because of extensive residual 
disease with metastasis. 
• 1 patient is disease free after getting full course of chemotherapy without surgery. 
• Remaining 20 patients underwent hepatic resection. There was no intra operative 
mortality. Among these 20 patients, 13 patients are disease free with near follow-up 3 
years. Other 7 patients died. 
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DISCUSSION 
 
Hepatoblastoma accounts around 80% of malignant liver tumors among pediatric age group1,2. 
Till 1970, surgery was only treatment modality for HB. In the past children with HB were treated 
with surgery alone and there was around 30% relapse rate. Then we gradually came to know that 
HB is a chemo sensitive tumor. Tremendous advances in chemotherapy occurred in last 2 
decades. In recent era, successful treatment of HB includes neoadjuvant chemotherapy, surgery 
and adjuvant chemotherapy. 
This is a retrospective study with follow-up of children with hepatoblastoma during the period 
from January 2003 to December 2012 at Christian Medical College and Hospital, Vellore 
(CMCH). All 28 children (N=28) who came under pediatric surgery and pediatric oncology were 
included in this study.  
In our study, average age of presentation was 28.22 months and 57.14% of children belonged to 
1-5 years of age group. Male: female ratio was 3.6:1 and it was compared to some of the 
previous reports. All 28 children presented with abdominal mass. 3 of them presented with 
jaundice due to central quadrant tumor and 1 with male isosexual precocious puberty.  
Trucut biopsy (82.14%) was the commonest mode of diagnosis. 14.28% children were diagnosed 
on the basis of CT findings and raised AFP. One child (3.57%) had undergone open biopsy.  
HB with low AFP at diagnosis will have extensive disease, poor response to chemo, and also 
poor outcome 49. In our study, 1 child with small cell undifferentiated (SCU; formerly anaplastic) 
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subtype presented with low AFP value (4.32 IU/ml) at presentation. All the others presented with 
>100 IU/ml AFP (Max. value 3500000 IU/ml). 
Survival is influenced by histopathological subtypes. Fetal subtype has favorable prognosis. But 
small cell undifferentiated and macrotrabecular variant have unfavorable outcome 6,50. In our 
study 60.71% was epithelial variety and 39.28% was mixed epithelial and mesenchymal type. 
One child had small cell undifferentiated tumor and another child had macrotrabecular subtype. 
Both of them died. Another child developed macrotrabecular variant in metastasis and died. 
In our study we tried to find out the relationship between high β-HCG at presentation and 
outcome. Two children were presented with high β-HCG level and both of them died. Male child  
with high β-HCG presented with features of male isosexual precocious puberty. So high β-HCG 
at presentation is suggestive of poor outcome. 
At presentation all children had normal liver function and creatinine value except 3 of them who 
presented with obstructive jaundice due to central quadrant tumor. 
2 children presented with multiple lung metastasis. One child was not operated in view of 
marginally resectable liver tumor with persistent multiple lung metastasis after 4 courses of 
PLADO chemotherapy and he died. Other one is well and alive. 
Preoperatively on an average the children received 4 cycles of PLADO (cisplatin/doxorubicin 
combination chemotherapy), ranging from 2 to 6 cycles. 
One child had simultaneous presentation of Hepatoblastoma and right paravertebral 
neuroblastoma and he was treated successfully. 
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Following neoadjuvant chemotherapy, child with small cell undifferentiated tumor had AFP 
value of 2.68 IU/ml. In 4 children AFP value came in between 10-100 IU/ml and all of them are 
alive (survival 100%). The other 23 children had AFP value between 100 IU/ml and 30000 
IU/ml). Survival among these 23 children was 43%. 
In our series, among 28 patients, PRETEXT and POSTTEXT staging were done on 25 patients. 
PRETEXT staging distribution was as follows; PRETEXT Stage I 16% (n=4), Stage II 48% 
(n=12), Stage III 24% (n=6), and Stage IV 12% (n=3). The overall survival according to the 
PRETEXT stage was as follows: PRETEXT I, 50%; PRETEXT II, 91.66%; PRETEXT III, 
16.66%; and PRETEXT IV, 0%. 
In our series, Among 28 (N=28) patients, 20 patients underwent hepatic resection (71.42%). 
Remaining 7 patients did not undergo surgery. Extensive residual disease with metastasis was the 
major reason behind this. Among 20 patients, 7 had undergone right hemihepatectomy, 3 had 
undergone right trisectionectomy, 4 were treated with left hemihepatectomy, only 1 child had 
undergone left lateral sectionectomy and remaining 5 children had undergone segmentectomy. 
There was no intraoperative and immediate postoperative mortality. 
Postoperatively on an average children received 2 cycles of cisplatin and doxorubicin (PLADO). 
One patient seems cured with chemotherapy alone. This 3 years girl presented with exomphalos 
and liver mass was protruding through it. At presentation AFP was 856 IU/ml. The tumor was 
central in location and PRETEXT stage was III. 6 cycles of PLADO were given. POSTTEXT 
stage was III. Recent AFP value was 0.596 IU/ml. PET-CT was done, showing no tumor activity. 
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Disease free survival was 10 months. There might be association of Beckwith-Weidemann 
syndrome and hepatoblastoma. 
Among 28 children, 4 had recurrent disease at remaining liver tissue and 3 had distant metastasis 
at lung, brain and skull. All 7 patients died. 
In our series, 65% patients who underwent hepatic resection are disease free after mean follow-
up of approximately 3 years. One patient is disease free after getting full course chemotherapy 
without surgery. However 7 patients who were originally seen did not undergo surgery for a 
variety of reasons making the oveall survival 50%.  
In most series, the PRETEXT I survival is 100%. But in our series, it is 50%. Among 4 patients 
of PRETEXT I, 2 patients died. 1 patient had recurrence at remaining left lobe. Other patient had 
metastases at lung and brain. 
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CONCLUSION 
• Our experience with hepatoblastoma reaffirms the advantages of neoadjuvant 
chemotherapy, surgery and followed by adjuvant chemotherapy. 
 
• Children whose AFP values come down in between 10-100 IU/ml following neoadjuvant 
chemotherapy will have good prognosis. 
 
• Most important determining factor in the outcome of children with hepatoblastoma is a 
combination of complete surgical resection and chemotherapy. 
 
• Children with small cell undifferentiated (SCU, formerly Anaplastic) and 
macrotrabecular subtype will have poor prognosis. 
 
 
• Children with high β-HCG at presentation will have dismal outcome. 
 
• Children with unresectable tumor after neoadjuvant chemotherapy and children with 
recurrent tumor will have poor outcome. 
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RECOMMENDATIONS 
 
 
• Neoadjuvant chemotherapy is needed for all stages of hepatoblastoma. 
 
 
• For surgically unresectable, nonmetastatic disease involving both lobes, 
orthotopic liver transplantation is an emerging modality of treatment. 
 
 
• Primary liver transplantation may be associated with better disease-free survival 
as compared with rescue liver transplantation. 
 
 
• The potential benefit of transcatheter arterial chemoembolization or hepatic 
arterial chemoembolization over systemic chemotherapy as initial therapy for 
unresectable tumors will have to be determined. 
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ANNEXURE-I 
Christian Medical College, Vellore 
Department of Paediatric Surgery 
Clinical Profile of Children WithHepatoblastoma. 
Information sheet 
Your child has been invited to join a research study to look at the present status of your child to 
improve current knowledge of disease – liver tumour   (Hepatoblastoma) suffered by him/her. 
Please take whatever time you need to discuss the study with your family and friends, or anyone 
else you wish to. The decision to let you child join, or not to join, is up to you. 
In this research study, we are evaluating the outcome of Hepatoblastoma. This study will help 
other children who later come to hospital with the same complaints.  By agreeing to be a part of 
this study, you will contribute to recognizing early how severe the disease is and thereby starting 
appropriate treatment immediately. The severity of your disease and the final treatment received 
will be compared to the information collected from you in the beginning. 
WHAT IS INVOLVED IN THE STUDY? 
This study is follow up study and does not involve any intervention on your child. Your child 
and you will be asked  to give following information 
1. History – This includes details regarding your general health and the  illness which your 
child  been treated for 
2. Clinical examination – Includes evaluation by the attending doctor. 
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3. Investigations – Includes the results of relevant blood tests, radiological investigations, 
and biopsy reports. These will be collected from hospital records as well. 
We think this will take him/her  30minutes. 
Whether you accept or decline to be a part of this study will not affect your further treatment at 
this hospital. 
Your child can stop participating at any time.  If your child stops he/she will not lose any 
benefits. 
RISKS 
There is no disadvantage or complication that can happen to you by participating in this study as 
this study does not interfere in the treatment provided by the care taker. 
BENEFITS TO TAKING PART IN THE STUDY? 
The benefits of joining in this study will be that the treating doctor will gain a better 
understanding of your child’s disease and its process thereby help in improving treatment 
protocols for the same. 
CONFIDENTIALITY 
Your child’s name will not be used when data from this study are published.  Every effort will be 
made to keep clinical records, research records, and other personal information confidential. 
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YOUR RIGHTS AS A RESEARCH PARTICIPANT? 
Participation in this study is voluntary. Your child has the right not to participate at all or to leave 
the study at any time. Deciding not to participate or choosing to leave the study will not result in 
any penalty or loss of benefits to which your child is entitled. 
CONTACTS FOR QUESTIONS OR PROBLEMS? 
In case of doubts/ questions, please contact Dr. SoumitraSaha, DeptOf Paediatric Surgery, 
CMCH Vellore. Ph no: +919159595579 
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Informed Assent form to participate in a clinical trial 
Christian Medical College, Vellore 
Department of Paediatric Surgery 
Clinical Profile of Children With Hepatoblastoma 
Study Title: 
Study Number: ____________ 
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________ 
Date of Birth / Age: ___________________________ 
(Subject) 
(i)  I confirm that I have read and understood the information sheet dated ____________ for 
the above study and have had the opportunity to ask questions.  
(ii)  I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected.  
(iii)  I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to look 
at my health records both in respect of the current study and any further research that may 
be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
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
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However, I understand that my identity will not be revealed in any information released 
to third parties or published.  
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). 
(v)  I agree to take part in the above study.  
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
Signatory’s Name: _________________________________         Signature:  
Or 
 
 
 
Representative: _________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 

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Signature of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name & Address of the Witness: ______________________________ 
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ANNEXURE-II 
A Clinical Profile of Children With Hepatoblastoma 
PROFORMA 
Serial NO.                                                                                                  Hospital No. 
Name:                                              Gender:                                                 
Address:                            
Mobile or Landline No.:                                                                
 Age of presentation(months): 
Mode of presentation: 
Mode of diagnosis:  
                                      1.Trucut Biopsy 
                                      2. Open Biopsy 
                                      3. Primary Surgery 
                                      4. Raised AFP and Radiological features 
Alpha-Fetoprotein (IU/ml): 
1. At presentation 
2. Before surgery 
3. In the last follow-up 
Beta-HCG at presentation (mIU/ml) 
Liver Fuction Test at presentation: 
Creatinine(mg/dl) at presentation: 
Histopathology: 
1. Special biopsy: (Trucut) 
2. Surgical specimen: 

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PRETEXT (Extent of tumor at diagnosis) 
Neoadjuvant chemotherapy: (Cisplatin + Doxorubicin) No of cycles: 
POSTTEXT (Extent of tumor after neoadjuvant chemotherapy): 
Location of tumor: 
Type of hepatectomy: 
If not operated. Why? 
Recurrences: Yes/ No 
Site of recurrence: 
Disease free survival: 
Death: 
1. Early 
2. Late 
Special features: 
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ANNEXURE-III 
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